Organogenesis (ORGO) Competitors

Biohaven (NYSE:BHVN) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.

Which has more risk & volatility, BHVN or ORGO?

Biohaven has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.

Do analysts recommend BHVN or ORGO?

Biohaven presently has a consensus target price of $62.54, suggesting a potential upside of 182.47%. Organogenesis has a consensus target price of $5.50, suggesting a potential upside of 12.02%. Given Biohaven's stronger consensus rating and higher possible upside, research analysts clearly believe Biohaven is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media favor BHVN or ORGO?

In the previous week, Biohaven had 16 more articles in the media than Organogenesis. MarketBeat recorded 22 mentions for Biohaven and 6 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.17 beat Biohaven's score of 0.70 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, BHVN or ORGO?

Organogenesis has higher revenue and earnings than Biohaven. Organogenesis is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$408.17M	-$9.39	-2.36
Organogenesis	$482.04M	1.29	$4.95M	-$0.02	-245.50

Do institutionals and insiders believe in BHVN or ORGO?

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Comparatively, 36.9% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is BHVN or ORGO more profitable?

Biohaven has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-225.12%	-158.89%
Organogenesis	-1.62%	-2.69%	-1.63%

Does the MarketBeat Community favor BHVN or ORGO?

Biohaven received 311 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 67.44% of users gave Biohaven an outperform vote while only 65.99% of users gave Organogenesis an outperform vote.

Company	Underperform	Outperform
Biohaven	Outperform Votes 408 67.44%	Underperform Votes 197 32.56%
Organogenesis	Outperform Votes 97 65.99%	Underperform Votes 50 34.01%

Summary

Biohaven beats Organogenesis on 10 of the 18 factors compared between the two stocks.